Core Viewpoint - The company has made significant progress in the development of a serum-free rabies vaccine, which is expected to fill a market gap as no serum-free rabies vaccines are currently approved globally [1][2]. Group 1: Product Development - The company's wholly-owned subsidiary, Aimei Honor (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the clinical trial site inspection and drug registration production site inspection for the serum-free rabies vaccine [1]. - The Phase III clinical trial results indicate that the serum-free rabies vaccine demonstrates good safety, immunogenicity, and durability, meeting the preset evaluation standards [1]. - The company has obtained the necessary production license for the serum-free rabies vaccine, marking a major technological breakthrough in the field [1]. Group 2: Market Opportunity - Rabies is a disease with a nearly 100% fatality rate once symptoms appear, making post-exposure vaccination critical [2]. - Currently, there are no registered serum-free rabies vaccines available in the market, with existing options being serum-based vaccines, which can cause allergic reactions [2]. - The Chinese rabies vaccine market is projected to reach 14.8 billion yuan by 2030, driven by product updates and increased vaccination rates [2]. Group 3: Competitive Position - The company is the second-largest supplier of rabies vaccines globally and aims to lead in the deep technological iteration and upgrade of rabies vaccines [3]. - A production facility that meets international standards for the serum-free rabies vaccine has been completed, and commercial-scale production has been validated, allowing for rapid market entry upon approval [3]. - The anticipated approval and market launch of the serum-free rabies vaccine are expected to significantly enhance the company's performance [3].